Betamethasone, in its injection form manufactured by Exela, was discontinued in mid-February 2023. However, it is important to note that this specific discontinuation does not mean all forms or manufacturers of betamethasone are unavailable.
Specific Discontinuation Details
The discontinuation of betamethasone injection specifically pertains to the product formerly supplied by Exela. This action was implemented in mid-February 2023. Patients and healthcare providers should be aware that while this particular product is no longer available, betamethasone remains a widely used corticosteroid.
General Availability of Betamethasone
Betamethasone is available in various forms and from multiple manufacturers. Its therapeutic uses span a broad range of conditions, including inflammatory, allergic, and autoimmune disorders. The discontinuation of one specific product from one manufacturer does not impact the general availability of other betamethasone formulations.
Common forms of betamethasone that continue to be available from various manufacturers include:
- Topical Creams and Ointments: Widely used for skin conditions like eczema, psoriasis, and dermatitis.
- Oral Tablets: Prescribed for systemic inflammatory conditions.
- Other Injectable Formulations: While Exela's injection was discontinued, other manufacturers may still produce betamethasone injections for specific medical uses.
To clarify the status of betamethasone:
| Betamethasone Form | Manufacturer | Status |
|---|---|---|
| Injection | Exela | Discontinued |
| Injection | Other | Generally Available |
| Cream/Ointment | Various | Generally Available |
| Tablet | Various | Generally Available |
Patients who have been prescribed betamethasone injection from Exela should consult their healthcare provider to discuss alternative formulations or manufacturers. For all other forms of betamethasone, the drug continues to be an accessible treatment option for appropriate medical conditions.
